Zacks: Analysts Anticipate Nabriva Therapeutics AG (NBRV) Will Post Quarterly Sales of $1.34 Million

Equities research analysts expect that Nabriva Therapeutics AG (NASDAQ:NBRV) will report $1.34 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Nabriva Therapeutics AG’s earnings, with the highest sales estimate coming in at $1.71 million and the lowest estimate coming in at $600,000.00. The business is expected to issue its next quarterly earnings results on Tuesday, August 8th.

On average, analysts expect that Nabriva Therapeutics AG will report full-year sales of $1.34 million for the current fiscal year, with estimates ranging from $3.48 million to $6.90 million. For the next year, analysts anticipate that the firm will post sales of $6.15 million per share, with estimates ranging from $1.20 million to $9.50 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Nabriva Therapeutics AG.

Several research firms have issued reports on NBRV. HC Wainwright restated a “buy” rating on shares of Nabriva Therapeutics AG in a research report on Friday, May 12th. Cantor Fitzgerald set a $16.00 price target on shares of Nabriva Therapeutics AG and gave the stock a “buy” rating in a research report on Monday, June 5th. Zacks Investment Research upgraded shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research report on Saturday, May 27th. Wedbush restated an “outperform” rating and issued a $13.00 price target on shares of Nabriva Therapeutics AG in a research report on Monday, May 15th. Finally, Needham & Company LLC restated a “buy” rating and issued a $15.00 price target on shares of Nabriva Therapeutics AG in a research report on Monday, March 27th. Seven analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus price target of $15.29.

ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Anticipate Nabriva Therapeutics AG (NBRV) Will Post Quarterly Sales of $1.34 Million” was published by Mideast Time and is the sole property of of Mideast Time. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.mideasttime.com/zacks-analysts-anticipate-nabriva-therapeutics-ag-nbrv-will-post-quarterly-sales-of-1-34-million/1799225.html.

Nabriva Therapeutics AG (NASDAQ:NBRV) traded up 2.98% during midday trading on Wednesday, reaching $9.34. The company had a trading volume of 6,084 shares. The company’s market capitalization is $254.14 million. The company’s 50 day moving average is $9.81 and its 200-day moving average is $9.28. Nabriva Therapeutics AG has a 52-week low of $3.52 and a 52-week high of $12.75.

In other Nabriva Therapeutics AG news, Director George Harrison Talbot sold 325 shares of Nabriva Therapeutics AG stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $100.56, for a total transaction of $32,682.00. Following the transaction, the director now directly owns 3,854 shares in the company, valued at approximately $387,558.24. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Hbm Healthcare Investments (Ca sold 32,831 shares of Nabriva Therapeutics AG stock in a transaction that occurred on Thursday, April 13th. The stock was sold at an average price of $11.24, for a total transaction of $369,020.44. Following the transaction, the insider now owns 2,660,689 shares in the company, valued at $29,906,144.36. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 166,873 shares of company stock worth $1,927,760.

A number of institutional investors have recently bought and sold shares of NBRV. Almanack Investment Partners LLC. bought a new stake in shares of Nabriva Therapeutics AG during the first quarter worth about $1,870,000. Geode Capital Management LLC bought a new stake in shares of Nabriva Therapeutics AG during the first quarter worth about $139,000. Wellington Management Group LLP raised its stake in shares of Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after buying an additional 193,951 shares during the period. Nationwide Fund Advisors bought a new stake in shares of Nabriva Therapeutics AG during the first quarter worth about $2,074,000. Finally, Vivo Capital LLC raised its stake in shares of Nabriva Therapeutics AG by 27.6% in the fourth quarter. Vivo Capital LLC now owns 4,021,559 shares of the biotechnology company’s stock worth $23,968,000 after buying an additional 869,859 shares during the period. Hedge funds and other institutional investors own 55.90% of the company’s stock.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic for systemic administration in humans. The Company develops both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP).new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:NBRV”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Get a free copy of the Zacks research report on Nabriva Therapeutics AG (NBRV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.